O'Mareen Spence, PhD

GSK, United States

Disclosure information not submitted.

Presentation(s):

• SC-27 - Intermediate/ Advanced Methods in Vaccine Safety and Effectiveness

  Saturday, August 23, 2025
  2:30 PM - 6:00 PM ET

• 1D-02 - Risk of Incident Supraventricular Tachycardia Following Exposure to Recombinant Zoster Vaccine in Adults ≥50 Years of Age in the United States

  Sunday, August 24, 2025
  10:45 AM - 11:00 AM ET

• 1D-03 - Recombinant Zoster Vaccine and Risk of Incident Guillain-Barré Syndrome in US Adults ≥ 65 Years of Age

  Sunday, August 24, 2025
  11:00 AM - 11:15 AM ET

• 3F - Older Adults Are All Heart

  Monday, August 25, 2025
  8:15 AM - 9:45 AM ET